Sep 01, 2020
Acquisition of IM HealthScience Completed
Aug 10, 2020
For The Sixth Year In A Row, In A Survey Of Gastroenterologists' Preferences For IBS Products, IBgard® Widens Its Already Preeminent "#1 Recommended"[1] Status
Aug 07, 2019
In the Longest-Ever String of Yearly Surveys on Gastroenterologists' Preferences for Recommending Products for IBS, IBgard Continues to Widen its Already Pre-Eminent "#1 Recommended"(1) Status
Aug 07, 2019
First-Ever 36 Month Real-World, Post-Marketing Surveillance Study Confirms The Excellent Safety And Tolerability Profile Of IBgard®, A Non-Prescription Product For IBS
Apr 30, 2019
Peer-Reviewed Medical Journal Publishes Landmark Study on Efficacy and Safety of FDgard® (COLM-SST), Demonstrating Rapid Reduction of Functional Dyspepsia (FD or Recurring, Meal-Triggered Indigestion) Symptoms Within 24 Hours
Nov 08, 2018
For The Fourth Year In A Row, U.S. Gastroenterologists Endorse Clinically Studied, Nonprescription IBS Product, IBgard®, By An Overwhelming Margin
Jul 03, 2018
For The Second Year In A Row, Gastroenterologists Nationwide Endorse Non-Prescription FDgard® For Functional Dyspepsia (Meal-Triggered Indigestion) [i]
Apr 19, 2018
Real-World Data From Surveillance Study Confirms Excellent Safety And Tolerability Profile Of IBgard® At 24 Months
Nov 01, 2017
U.S. Gastroenterologists Endorse Non-Prescription FDgard® For Functional Dyspepsia (Recurring Indigestion)
Oct 30, 2017
For The Third Year In A Row, U.S. Gastroenterologists Endorse Clinically Studied, Non-Prescription IBgard® For Irritable Bowel Syndrome (IBS), By Overwhelming Margin
Oct 18, 2017
Final Results Of Real-World Data From Observational Study Underscores High Levels Of Patient Satisfaction And Rapid Improvement Of Functional Dyspepsia (Recurring Indigestion) With Non-Prescription FDgard®
Aug 24, 2017
Real-World Data From Surveillance Study At 12 Months Confirms Excellent Safety And Tolerability Profile Of New, Non-Prescription FDgard® For Functional Dyspepsia